Novel light-operated repressor protein OptoLacI and application method thereof

OptoLacI, a photocontrolled repressor protein constructed by inserting the LOV domain into the LacI protein, solved the toxicity and complexity of the chemical induction system in E. coli, and achieved high-temporal and spatial resolution regulation and bidirectional induction of the photocontrol gene expression system, improving the System compatibility and induction rigor.

CN118894945APending Publication Date: 2024-11-05TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410765840.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-14
Filing Date
2024-06-14
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing chemical induction system in E. coli has problems such as cytotoxicity, high cost, and irreversible regulation. The control components of the photocontrol gene expression system are complex, complex operations, and the two-way regulatory tools are incomplete.

Method used

A new light-controlled repressor protein, OptoLacI, was developed. By inserting the LOV domain into a specific location of the LacI protein, a light-controlled gene expression system is constructed to achieve bidirectional induction of blue light and darkness, and has high spatial and temporal resolution.

Benefits of technology

High-temporal and spatial resolution regulation of gene expression is achieved, cytotoxicity and cost are reduced, operation is simplified, and more complete two-way regulation tools are provided, which improves system compatibility and induction rigor.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894945A_ABST
    Figure CN118894945A_ABST
Patent Text Reader

Abstract

The invention provides a novel light-operated repressor protein OptoLacI and a light-operated gene expression system constructed on the basis of the OptoLacI. The light-operated repressor protein OptoLacI and an inducer of a light-operated gene expression system are low in cost and easy to obtain; compared with other inducers, the inducer is safe, nontoxic or less in toxicity; the light-operated gene expression system disclosed by the invention can realize bidirectional dynamic regulation and control and is easy to control. The invention also provides application of the light-operated expression system in protein production and metabolic engineering.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of protein engineering or synthetic biology in biotechnology, specifically to gene expression regulation, and more specifically to a novel light-controlled repressor protein OptoLacI and a light-controlled gene expression system constructed using OptoLacI, as well as the application of the light-controlled expression system in protein production and metabolic engineering. Background Art

[0002] In metabolic engineering practice, the introduction of exogenous pathways leads to uneven distribution of material and energy flows, imbalance of endogenous metabolic resources, and thus causes growth defects of production strains and limited product yields. Therefore, in metabolic engineering practice, improving metabolic imbalance by regulating metabolic pathways is a common strategy, including enhancing precursor supply and substrate or product transport through gene overexpression, knocking out competitive pathways, and overexpressing genes related to target pathways. As the preferred host for the production of a variety of compounds, Escherichia coli has a wide range of application value in the fields of chemistry, food, pharmaceuticals, agriculture, and energy. In 1961, French scientists F. Jacob and J. Monod established the lactose operon model of Escherichia coli. The lactose operon induction system based on this model is the most commonly used induction system in Escherichia coli. In the absence of lactose analogue isopropyl β-d-1-thiogalactoside (IPTG), the repressor protein LacI binds to the lac operon (LacO) upstream of the target gene to inhibit the transcription of the target gene; when IPTG binds to the repressor protein LacI, the LacI repressor protein dissociates from the lacO site, thereby initiating the transcription of the target gene. In metabolic engineering practice, IPTG is mainly added to achieve the regulation of metabolic pathways. However, in the practice of metabolic engineering and industrial production of proteins, the chemical inducer IPTG has the disadvantages of cytotoxicity, high cost, irreversible induction, and cannot achieve precise regulation in time and space. Therefore, researchers have been constantly trying to find its alternatives. With the continuous development of optogenetic tools, the low toxicity, easy access, reversible regulation and low cost of light make it an ideal way to induce gene expression. However, existing light-controlled gene expression systems face problems such as complex control components, complicated operations, and imperfect bidirectional regulatory tools. SUMMARY OF THE INVENTION

[0004] In response to the problems of cytotoxicity, high cost, irreversible regulation, etc. in the existing chemical induction of Escherichia coli mentioned above, as well as the problems of complex control components, complex operation and imperfect bidirectional regulation tools faced by the light-controlled Escherichia coli gene expression system, the present invention first provides a new light-controlled repressor protein OptoLacI, and develops two sets of light-controlled gene expression systems based on OptoLacI to achieve bidirectional induction of blue light and darkness. It has high temporal and spatial resolution and has excellent characteristics in protein expression and metabolic engineering.

[0005] In one aspect, the present invention provides a light-controlled repressor protein comprising a LacI protein and a LOV domain inserted between adjacent amino acids in the Loop-1, Loop-2 or Loop-3 region of the LacI protein.

[0006] In certain embodiments, the LOV domain is a LOV2 domain; preferably, the LOV domain is selected from the LOV2 domain (AsLOV2) of the oat phytochrome 1 gene, the photosensitive protein EL222 from Staphylococcus aureus, the photosensitive domain LOV2 from Arabidopsis thaliana, or mutants thereof; preferably, the mutant is a cyclic rearrangement mutant or a mutant with altered response speed; preferably, the LOV domain is AsLOV2, for example, comprising the sequence shown in SEQ ID NO:1; preferably, the LOV domain is cpLOV27, for example, comprising the sequence shown in SEQ ID NO:2.

[0007] In certain embodiments, the insertion position is selected from the following amino acid positions of the LacI protein: between positions 335 and 336, between positions 314 and 315, between positions 315 and 316, between positions 316 and 317, between positions 334 and 335, between positions 336 and 337, between positions 337 and 338, between positions 338 and 339, between positions 152 and 153; preferably, the insertion position is selected from between positions 335 and 336 of the LacI protein.

[0008] In certain embodiments, the insertion position is selected from the following amino acid positions of the LacI protein: between positions 311 and 312, between positions 153 and 154; preferably, the insertion position is selected from between positions 311 and 312 of the LacI protein.

[0009] In certain embodiments, the LacI protein is wild-type; preferably, the wild-type LacI protein comprises the sequence shown in SEQ ID NO:26.

[0010] In certain embodiments, the LacI protein is a modified LacI protein, which comprises an amino acid replacement selected from the following compared to the wild-type LacI protein: (i) the amino acid at position 220 is replaced by F, and / or, (ii) the amino acid at position 84 is replaced by E, C, S, T, or I; preferably, the wild-type LacI protein comprises the sequence shown in SEQ ID NO: 26; preferably, the modified LacI protein comprises the sequence shown in SEQ ID NO: 27 or 28, or comprises a sequence in which the amino acid at position 84 is replaced by C, S, T, or I compared to SEQ ID NO: 27 or 28.

[0011] In certain embodiments, the N-terminus and / or C-terminus of the LOV domain is optionally connected to the LacI protein via a peptide linker.

[0012] In certain embodiments, the light-controlled repressor protein comprises a sequence as shown in any one of SEQ ID NOs: 11, 29, 6-8, 10, 12-14, 16 or comprises a sequence as shown in SEQ ID NO: 3 or 17; preferably, the light-controlled repressor protein comprises a sequence as shown in SEQ ID NO: 11 or 29; preferably, the light-controlled repressor protein comprises a sequence as shown in SEQ ID NO: 3.

[0013] In one aspect, the present invention provides a nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein described above.

[0014] In one aspect, the present invention provides a vector comprising the nucleic acid construct described above.

[0015] In certain embodiments, the vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises the nucleotide sequence encoding the light-controlled repressor protein, and the second nucleic acid construct comprises a promoter, a LacO operator, and a target gene or a cloning site for integrating a target gene; preferably, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes.

[0016] In certain embodiments, the second nucleic acid construct comprises a LacO operator selected from LacO1, LacOid, or a combination thereof.

[0017] In certain embodiments, the LacO operator gene contained in the second nucleic acid construct comprises at least one copy (e.g., 1 to 8 copies, such as 1, 2, 3, 4, 5, 6, 7, 8, for example 3 to 5) of the LacO1 operator sequence; preferably, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO:24.

[0018] In certain embodiments, the LacO operator contained in the second nucleic acid construct further contains LacOid; preferably, the LacOid is located downstream of LacO1; preferably, the LacO operator contains LacO1 and LacOid from 5' to 3' direction.

[0019] In certain embodiments, the promoter comprised by the second nucleic acid construct is selected from the group consisting of T7 promoter of T7 phage, lac promoter, tac promoter, and lacUV5 promoter.

[0020] In certain embodiments, the first nucleic acid construct further comprises a promoter operably linked to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter.

[0021] In one aspect, the present invention provides a host cell comprising the nucleic acid construct or vector described above; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli.

[0022] In certain embodiments, the host cell is Escherichia coli, which has an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; preferably, the endogenous LacI gene of the Escherichia coli is destroyed; preferably, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence; preferably, one copy of the endogenous LacI gene of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the other copy of the endogenous LacI gene is knocked out.

[0023] In certain embodiments, the E. coli further comprises the vector comprising the first nucleic acid construct and the second nucleic acid construct as described above.

[0024] In one aspect, the present invention provides a system for regulating the expression of a gene of interest, comprising:

[0025] (1) a first nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein described above;

[0026] (2) A second nucleic acid construct comprising a promoter, a LacO operator, and a second nucleic acid construct of a target gene.

[0027] In certain embodiments, the second nucleic acid construct is as defined in any of the embodiments of any of the above aspects.

[0028] In certain embodiments, the second nucleic acid construct comprises a plurality of target genes arranged in tandem; preferably, an additional promoter is optionally inserted between the plurality of target genes.

[0029] In certain embodiments, the first nucleic acid construct further comprises a promoter operably linked to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter.

[0030] In certain embodiments, the system comprises at least two of the first nucleic acid constructs, one of which is integrated into the genome of the host cell, and the other is present on a vector (e.g., an expression vector) with the second nucleic acid construct; wherein the at least two first nucleic acid constructs are identical or different from each other; preferably, the vector is the vector comprising the first nucleic acid construct and the second nucleic acid construct as described above.

[0031] In certain embodiments, the first nucleic acid construct and the second nucleic acid construct are present on a vector (eg, an expression vector); preferably, the vector is the vector comprising the first nucleic acid construct and the second nucleic acid construct as described above.

[0032] In certain embodiments, the first nucleic acid construct is integrated into the genome of the host cell and the second nucleic acid construct is present on a vector (eg, an expression vector).

[0033] In certain embodiments, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli.

[0034] In one aspect, the present invention provides a kit comprising a host cell and an expression vector, wherein:

[0035] (1) The host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; and the expression vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises an exogenous nucleotide sequence encoding the light-controlled repressor protein, and the second nucleic acid construct comprises a promoter, a LacO operator gene, and a cloning site for integrating a target gene; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli;

[0036] or,

[0037] (2) The host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; and the expression vector comprises the second nucleic acid construct; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli;

[0038] or,

[0039] (3) The host cell has not integrated the exogenous nucleotide sequence encoding the light-controlled repressor protein into its genome; and the expression vector comprises the first nucleic acid construct and the second nucleic acid construct; preferably, the host cell is a prokaryotic cell, such as Escherichia coli.

[0040] In certain embodiments, the second nucleic acid construct is as defined in any of the embodiments of any of the above aspects.

[0041] In certain embodiments, the first nucleic acid construct further comprises a promoter operably linked to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter.

[0042] In certain embodiments, (1) or (2) the host cell is Escherichia coli, which has an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; preferably, the endogenous LacI gene of the Escherichia coli is destroyed; preferably, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence; preferably, one copy of the endogenous LacI gene of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the other copy of the endogenous LacI gene is knocked out.

[0043] In one aspect, the present invention provides a method for regulating the expression of a gene of interest, comprising:

[0044] (1) providing the system described above in a host cell;

[0045] (2) Cultivating the host cell under conditions that allow expression of the target gene and inducing expression of the target gene.

[0046] In certain embodiments, step (1) comprises:

[0047] (i) providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; preferably, the expression vector is the vector comprising the first nucleic acid construct and the second nucleic acid construct described above; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli;

[0048] or,

[0049] (ii) providing an expression vector comprising the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli;

[0050] or,

[0051] (iii) providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell does not contain the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome; preferably, the expression vector is the vector comprising the first nucleic acid construct and the second nucleic acid construct as described above; preferably, the host cell is a prokaryotic cell, such as Escherichia coli.

[0052] In certain embodiments, (i) or (ii) the host cell is Escherichia coli, which has an exogenous nucleotide sequence encoding the light-controlled repressor protein described above integrated into its genome; preferably, the endogenous LacI gene of the Escherichia coli is destroyed; preferably, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence; preferably, one copy of the endogenous LacI gene of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the other copy of the endogenous LacI gene is knocked out.

[0053] In certain embodiments, the insertion position in the light-controlled repressor protein is selected from the following amino acid positions of the LacI protein: between positions 335 and 336, between positions 314 and 315, between positions 315 and 316, between positions 316 and 317, between positions 334 and 335, between positions 336 and 337, between positions 337 and 338, between positions 338 and 339, between positions 152 and 153; preferably, the insertion position is selected from between positions 335 and 336 of the LacI protein; the induction conditions described in step (2) include: culturing the host cell under dark conditions to induce the expression of the target gene; preferably, the method further includes culturing the recombinant host cell under blue light conditions to inhibit the expression of the target gene.

[0054] In certain embodiments, the insertion position in the light-controlled repressor protein is selected from the following amino acid positions of the LacI protein: between positions 311 and 312, between positions 153 and 154; preferably, the insertion position is selected from between positions 311 and 312 of the LacI protein; the induction conditions described in step (2) include: culturing the host cells under blue light conditions to induce the expression of the target gene; preferably, the method further includes culturing the host cells under dark conditions to inhibit the expression of the target gene.

[0055] In one aspect, the present invention provides the light-controlled repressor protein, nucleic acid construct, vector, host cell, system, or kit described above, for use in regulating the expression of a target gene; preferably, the use includes regulating protein expression; preferably, the use includes regulating metabolic pathways and / or biosynthesis. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] The invention is further described in the following non-limiting drawings:

[0057] Figure 1 :Screening results of photoswitchable LacI mutants.

[0058] Figure 2 : Schematic diagram of the light-controlled Escherichia coli genome structure.

[0059] Figure 3 :Effect of tandem LacO1 number on darkness-inducible gene expression strains.

[0060] Figure 4 :Effect of tandem LacO1 number on blue light-induced gene expression strains.

[0061] Figure 5 : Optimization results of the induction intensity of the darkness-inducible gene expression system.

[0062] Figure 6 : Effects of different promoters on the darkness-inducible gene expression system.

[0063] Figure 7 : Optimization results of the induction multiple of the dark-inducible gene expression system.

[0064] Figure 8 :The results of the application of the dark-induced gene expression system in protein expression. A is the expression result of alkalineprotease (36.8KD); B is the expression result of PETase (29.0KD); C is the expression result of GDH (29.4KD). M represents protein marker (in KD), and the numbers 0, 2, 4, 6, 9, and 12 represent the sample numbers of cell lysates at different dark-induced times (0h, 2h, 4h, 6h, 9h, and 12h).

[0065] Fig. 9 :The effect diagram of the application of blue light-induced gene expression system in protein expression. Figure A is the expression result diagram of FadA (41.6KD); Figure B is the expression result diagram of MdhII (35.9KD). M represents protein marker (unit is KD), L represents cell lysate sample induced by blue light for 9 hours, and L represents cell lysate sample cultured in the dark for 9 hours.

[0066] Fig.10 : Schematic diagram of the expression cassette of key genes in 1,3-propanediol biosynthesis.

[0067] Fig.11 :Application of dark induction system in metabolic pathway flux control. No IPTG was added during the fermentation of S1-IPTG:BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA; S1-IPTG:BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA was added at OD 600 =0.1-0.6 when adding IPTG; S2LL:BL21_Dark_D v1 / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA Fermentation was always carried out under blue light; S2LD:BL21_Dark_D v1 / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA at OD 600 =0.1-0.6, switch to light-proof state.

[0068] Fig.12 : Comparison of the expression effects of GFP using the light-controlled gene expression system and the IPTG-induced system. DETAILED DESCRIPTION OF THE INVENTION

[0070] definition

[0071] Unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0072] As used herein, the term "comprising" and its variations are used synonymously with the term "including" and its variations, and are open, non-limiting terms. Although the terms "comprising" and "including" have been used herein to describe various embodiments, the terms "consisting essentially of" and "consisting of" may be used instead of "comprising" and "including" to provide more specific embodiments, and are also disclosed.

[0073] As used herein, the articles “a,” “an,” and “the” mean “at least one,” unless the context in which the article is used clearly indicates otherwise.

[0074] As used herein, the terms "Lac repressor" or "LacI protein" have the same meaning and are used interchangeably. The sequence of LacI protein is well known to those skilled in the art and can be found in various public databases, such as GenBank:CAF2498598.1. In this article, when referring to the amino acid position of LacI protein, it is described with reference to the sequence shown in SEQ ID NO:26. For example, the expression "amino acid residue 335 of LacI protein" refers to the amino acid residue 335 of the sequence shown in SEQ ID NO:26 and its corresponding position. The corresponding position refers to the position in the sequence to be compared that is equivalent to the specific amino acid position in SEQ ID NO:26 when the sequence to be compared is optimally aligned with SEQ ID NO:26 (i.e., to obtain the highest percentage identity).

[0075] As used herein, the term "LOV domain" refers to a light-oxygen-voltage (LOV) domain, generally derived from a light-sensing protein of a plant, algae or bacteria. Preferably, the LOV domain is a LOV2 domain, preferably from oats, Staphylococcus australis or Arabidopsis thaliana. In certain exemplary embodiments, the LOV domain has an amino acid sequence as shown in SEQ ID NO: 1, 30 or 31, or a sequence having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identity thereto.

[0076] As used herein, the term "circular permutation" refers to connecting the original N-terminus and C-terminus of a protein through a linker and introducing a new terminus by cleaving the original peptide bond of the protein. The new protein thus formed is called a circularly permuted mutant.

[0077] As used herein, the term "gene" is broadly used to refer to a DNA nucleic acid associated with a biological function. As used herein, "target gene" refers to any nucleic acid sequence that may and / or will be significant for controlling its transcription level.

[0078] As used herein, the term "transcription" refers to the synthesis of RNA from a DNA template; the term "translation" refers to the synthesis of a polypeptide from an mRNA template. Transcription and translation are collectively referred to as "expression".

[0079] As used herein, the term "operably linked" refers to the functional connection of elements, wherein the elements are in a relationship that allows them to operate in an intended manner. For example, for a promoter, the functional connection between the promoter and the target gene is such that the promoter sequence is able to initiate transcription of the target gene.

[0080] As used herein, the term "vector" refers to a nucleic acid carrier into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses, etc. One type of vector is an episomal vector, that is, a nucleic acid capable of extrachromosomal replication. Another type of vector is an integrative vector, which is designed to recombine with the genetic material of a host cell. The vector usually contains one or more restriction endonuclease recognition sites and / or sites for site-specific recombination, and exogenous DNA fragments can be cut and connected to these sites in the vector. The vector may contain a variety of elements for controlling expression, including, but not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection element, and a reporter gene. In addition, the vector may also contain a replication initiation site.

[0081] As used herein, the term "expression cassette" refers to a combination of genes to which control elements are operably linked for expression. Control elements may include, for example, promoter sequences, start codons, stop codons, terminators. The expression cassette may contain additional regulatory sequences and other sequences, such as enhancers, signal sequences, enhancers, introns, IRES sequences, etc.

[0082] As used herein, the term "promoter" refers to an expression control element that allows RNA polymerase binding and transcription initiation.

[0083] As used herein, the term "host cell" refers to cells that can be used to introduce a vector, including but not limited to prokaryotic cells, fungal cells, insect cells, mammalian cells, and plant cells.

[0084] Light-operated repressor protein

[0085] After research by the inventors, the present invention was completed based on the following insights and discoveries, and specifically provides the following aspects.

[0086] Lac repressor protein (LacI) is a protein that regulates the transcription of genes required for lactose metabolism in Escherichia coli. LacI is composed of 360 amino acid residues, and its structure includes two domains, the N-terminal and C-terminal. The N-terminal domain (amino acids 1-59) contains the helix-turn-helix motif necessary for binding to DNA, and the C-terminal domain contains the binding site for chemical inducers and their analogs. The 30 amino acids at the C-terminal end mediate the tetramerization of the repressor protein. Two subunits in the LacI tetramer bind to the operator gene LacO1, and the other two subunits bind to the operator gene LacO2 or LacO3, forming a loop between the operator genes, thereby preventing RNA polymerase from binding to the promoter. The binding of LacI to the chemical inducer IPTG enables it to maintain a stable protein conformation, which has a low affinity with the operator gene, thereby reducing the occupancy of the operator gene and the repressor protein LacI is in a derepressed state, initiating the transcription of downstream genes. The blue-light-responsive light-oxygen-voltage sensing domain 2 (LOV2) domain has a small molecular weight (100-140 amino acids) and its chromophore flavin mononucleotide (FMN) is ubiquitous in various types of cells. Therefore, LOV2 is a widely used light-controlled element. In various types of cells, the LOV2 domain has been used for reversible and spatiotemporal manipulation of cell signaling and behavior, including reversible control of intracellular protein degradation, protein-protein interactions, and protein localization. The C-terminus of the LOV2 domain contains a Jα helix. Under dark conditions, the Jα helix forms a stable conformation between the β-sheet located in the Per-Arnt-Sim (PAS) core domain; under blue light irradiation, the conserved cysteine ​​(Cysteine) in the LOV2 domain and FMN covalently bind, causing the conserved glutamine (Glutamine) residue to rotate, ultimately leading to a change in the conformation of the Jα helix and its separation from the central β-sheet. Based on the repressor protein LacI and the light-controlled element LOV2, it is possible for us to mutate both and construct a new light-controlled repressor protein for precise regulation of gene expression.

[0087] In one aspect, the present invention provides a light-controlled repressor protein comprising a LacI protein and a LOV domain inserted between adjacent amino acids in the Loop-1, Loop-2 or Loop-3 region of the LacI protein.

[0088] In certain embodiments, the Loop-1 region of the LacI protein refers to amino acid positions 311-317; the Loop-2 region refers to amino acid positions 333-340; and the Loop-3 region refers to amino acid positions 152- 156. In this document, when referring to the amino acid positions of the LacI protein, the sequence shown in SEQ ID NO: 26 is referenced for description.

[0089] In certain embodiments, the N-terminus and / or C-terminus of the LOV domain is directly linked to the LacI protein.

[0090] In certain embodiments, the N-terminus and / or C-terminus of the LOV domain is connected to the LacI protein via a peptide linker (eg, a peptide linker comprising one or several flexible amino acids).

[0091] LOV domain

[0092] Any LOV domain known in the art can be used in the present invention. In certain embodiments, the LOV domain is a LOV2 domain. LOV2 from different species all belong to the light response domain and play the same role in different species; and, in terms of structure, the three-dimensional structures of LOV2 from different species are highly similar, and the corresponding allosteric principles are the same. Therefore, LOV2 domains from different species are all suitable for the present invention.

[0093] In certain embodiments, the LOV domain is selected from the LOV2 domain of the oat phytochrome 1 gene (AsLOV2), the photosensitive protein EL222 from Staphylococcus aureus, the photosensitive domain LOV2 from Arabidopsis thaliana, or mutants thereof.

[0094] In certain embodiments, the mutant is a cyclic rearrangement mutant. In this article, "cyclic rearrangement" has a meaning well known to those skilled in the art, which refers to connecting the original N-terminus and C-terminus of a protein through a linker and introducing a new terminus by cleaving the original peptide bond of the protein.

[0095] In certain embodiments, the mutant is a mutant with a changed response speed. Such mutants are known to those skilled in the art, and typically may include mutations selected from the following: V461I, V74I, L165I, wherein the amino acid position refers to the position in AsLOV2, and the corresponding position in other LOV domains can be determined by sequence alignment (see, for example, Zoltowski, BD, B. Vaccaro, and BR Crane, Mechanism-based tuning of a LOV domain photoreceptor. Nature Chemical Biology, 5(11): 827-834 (2009)). Introducing a mutation that changes the response speed of LOV2 does not change the mechanism and fact that it undergoes conformational changes in response to blue light, and thus these mutants are also applicable to the present invention.

[0096] In certain embodiments, the LOV domain is AsLOV2. In certain embodiments, the AsLOV2 comprises the amino acid sequence shown in SEQ ID NO:1.

[0097] In certain embodiments, the LOV domain is a circularly permuted mutant of AsLOV2. In certain embodiments, the circularly permuted mutant of AsLOV2 is cpLOV27, which comprises the amino acid sequence shown in SEQ ID NO:2.

[0098] In certain embodiments, the LOV domain is the light-sensitive protein EL222 from Staphylococcus aureus, for example comprising the amino acid sequence shown in SEQ ID NO:30.

[0099] In certain embodiments, the LOV domain is the photosensitive domain LOV2 from Arabidopsis thaliana, for example, comprising the amino acid sequence shown in SEQ ID NO:31.

[0100] LacI protein

[0101] In certain embodiments, the LacI protein is a wild-type LacI protein. In certain embodiments, the wild-type LacI protein comprises the sequence shown in SEQ ID NO:26.

[0102] In certain embodiments, the LacI protein is a modified LacI protein, which comprises an amino acid substitution selected from the following compared to the wild-type LacI protein: (i) the amino acid at position 220 is substituted with F, and / or, (ii) the amino acid at position 84 is substituted with E, C, S, T, or I.

[0103] In certain embodiments, the modified LacI protein comprises the sequence shown in SEQ ID NO: 27 or 28, or comprises the following sequence: the amino acid at position 84 is substituted with C, S, T, or I compared with SEQ ID NO: 27 or 28.

[0104] In certain embodiments, the modified LacI protein comprises the sequence shown in SEQ ID NO:27 or 28.

[0105] Light-operated repressor protein that responds to darkness

[0106] In certain embodiments, the light-controlled repressor protein of the present invention has an activity that responds to darkness. In this article, "activity that responds to darkness" means that the light-controlled repressor protein does not play a repressive role under dark conditions and allows the expression of the target gene. The light-controlled repressor protein preferably plays a repressive role under blue light (e.g., 430-495nm, such as 450-480nm) conditions and inhibits the expression of the target gene.

[0107] In certain embodiments, the insertion position in the light-operated repressor protein responsive to darkness is selected from the following amino acid positions of the LacI protein: between positions 335 and 336 (such as Loop-2 (Q335-T336)), between positions 314 and 315 (such as Loop-1 (K314-G315)), between positions 315 and 316 (such as Loop-1 (G315-N316)), between positions 316 and 317 (such as Loop-1 (N316- Q317)), between positions 334 and 335 (such as Loop-2 (T334-Q335)), between positions 336 and 337 (such as Loop-2 (T336-A337)), between positions 337 and 338 (such as Loop-2 (A337-S338)), between positions 338 and 339 (such as Loop-2 (S338-P339)), between positions 152 and 153 (such as Loop-3 (D152-Q153)).

[0108] In certain embodiments, the insertion position in the darkness-responsive light-operated repressor protein is between positions 335 and 336 of the LacI protein (eg, Loop-2 (Q335-T336)).

[0109] In some embodiments, the light-operated repressor protein responsive to darkness comprises an amino acid sequence as shown in any one of SEQ ID NOs: 11, 29, 6-8, 10, 12-14, 16. In some embodiments, the light-operated repressor protein responsive to darkness comprises an amino acid sequence as shown in SEQ ID NO: 11 or 29.

[0110] Light-controlled repressor protein responsive to blue light

[0111] In certain embodiments, the light-controlled repressor protein of the present invention has an activity that responds to blue light. In this article, "activity that responds to blue light" means that the light-controlled repressor protein does not play a repressive role under blue light (e.g., 430-495nm, such as 450-480nm) conditions and allows the expression of the target gene. The light-controlled repressor protein preferably plays a repressive role under dark conditions and inhibits the expression of the target gene.

[0112] In certain embodiments, the insertion position in the light-controlled repressor protein responsive to blue light is selected from the following amino acid positions of the LacI protein: between positions 311 and 312 (such as Loop-1 (Q311-A312)), between positions 153 and 154 (such as Loop-3 (Q153-T154)).

[0113] In certain embodiments, the insertion position in the light-controlled repressor protein responsive to blue light is between positions 311 and 312 of the LacI protein (eg, Loop-1 (Q311-A312)).

[0114] In some embodiments, the light-controlled repressor protein responsive to blue light comprises the amino acid sequence shown in SEQ ID NO: 3 or 17. In some embodiments, the light-controlled repressor protein responsive to blue light comprises the amino acid sequence shown in SEQ ID NO: 3.

[0115] The light-controlled repressor protein of the present invention can be prepared by various methods known in the art, for example, by genetic engineering methods (recombinant technology) or by chemical synthesis methods (such as Fmoc solid phase method). The light-controlled repressor protein of the present invention is not limited by its production method.

[0116] Nucleic acid constructs and vectors

[0117] In another aspect, the present invention provides a nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein of the present invention.

[0118] In another aspect, the present invention provides a vector comprising the nucleic acid construct as described above.

[0119] In certain embodiments, the vector is an expression vector. In certain embodiments, the vector is a plasmid.

[0120] In certain embodiments, the vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the second nucleic acid construct comprises a promoter, a LacO operator, and a target gene.

[0121] In certain embodiments, the vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the second nucleic acid construct comprises a promoter, a LacO operator, and a cloning site for integrating the target gene (e.g., a multiple cloning site MCS).

[0122] In certain embodiments, the second nucleic acid construct comprises a LacO operator selected from LacO1, LacOid, or a combination thereof.

[0123] In some embodiments, the LacO operator gene included in the second nucleic acid construct comprises at least one copy (e.g., 1 to 8, such as 1, 2, 3, 4, 5, 6, 7, 8, such as 3 to 5) of the LacO1 operator sequence. In some embodiments, the LacO operator gene included in the second nucleic acid construct comprises 3 to 5 copies of the LacO1 operator sequence. In some embodiments, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO: 24.

[0124] In some embodiments, the LacO operator comprised by the second nucleic acid construct comprises LacO1 and LacOid. In some embodiments, the LacOid is located downstream of LacO1. In some embodiments, the LacO operator comprises LacO1 and LacOid from 5' to 3' direction.

[0125] In certain embodiments, the promoter included in the second nucleic acid construct can be any promoter recognized by the RNA polymerase encoded by the RNAP gene included in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell. In certain embodiments, the promoter included in the second nucleic acid construct is selected from the T7 promoter, lac promoter, tac promoter, lacUV5 promoter of T7 phage.

[0126] In certain embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein of the present invention. In certain embodiments, the promoter included in the first nucleic acid construct can be any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell. In certain embodiments, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter.

[0127] In certain embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes of the same vector.

[0128] In certain embodiments, the vector is a plasmid based on pET-28a, the original gene sequence encoding LacI in pET-28a is replaced by a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced by the LacO operator gene contained in the second nucleic acid construct.

[0129] Host cells

[0130] In another aspect, the present invention provides a host cell comprising the nucleic acid construct or vector as described above.

[0131] In certain embodiments, the host cell is a prokaryotic cell.

[0132] In certain embodiments, the host cell is Escherichia coli.

[0133] In certain embodiments, the host cell is Escherichia coli, and the exogenous nucleotide sequence encoding the light-controlled repressor protein of the present invention is integrated into the genome of the Escherichia coli.

[0134] In certain embodiments, the endogenous LacI gene of the Escherichia coli is destroyed. In certain embodiments, the destruction includes: loss-of-function mutations (e.g., addition, deletion and / or substitution of one or more bases), deletion or substitution with an exogenous nucleotide sequence. "Loss-of-function mutation" refers to a mutation that causes the protein encoded and expressed by the mutant gene to lose its biological functional activity. Loss-of-function mutations include, but are not limited to, missense mutations, nonsense mutations, frameshift mutations, base deletions, base substitutions, base additions, and any combination thereof (e.g., deletion or substitution or addition of gene fragments), as long as the gene containing the loss-of-function mutation cannot produce or express a protein with biological functional activity.

[0135] In certain embodiments, both copies of the endogenous LacI gene of the E. coli are replaced with the exogenous nucleotide sequence.

[0136] In certain embodiments, one copy of the endogenous LacI gene of the E. coli is replaced with the exogenous nucleotide sequence, and another copy of the endogenous LacI gene is knocked out.

[0137] In certain embodiments, the integration of exogenous nucleotide sequences contained in the host cell and / or the disruption of endogenous genes can be achieved by any gene editing system well known to those skilled in the art. Exemplary gene editing systems include CRISPR / Cas, ZFN, TALEN, etc.

[0138] In certain embodiments, the Escherichia coli having an exogenous nucleotide sequence encoding the light-controlled repressor protein of the present invention integrated into its genome may further comprise the vector (eg, expression vector) comprising the first nucleic acid construct and the second nucleic acid construct as described above.

[0139] Systems for regulating the expression of target genes

[0140] In another aspect, the present invention provides a system for regulating the expression of a target gene, comprising:

[0141] (1) a first nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein of the present invention;

[0142] (2) A second nucleic acid construct comprising a promoter, a LacO operator, and a second nucleic acid construct of a target gene.

[0143] In certain embodiments, the second nucleic acid construct comprises a LacO operator selected from LacO1, LacOid, or a combination thereof.

[0144] In some embodiments, the LacO operator gene included in the second nucleic acid construct comprises at least one copy (e.g., 1 to 8, such as 1, 2, 3, 4, 5, 6, 7, 8, such as 3 to 5) of the LacO1 operator sequence. In some embodiments, the LacO operator gene included in the second nucleic acid construct comprises 3 to 5 copies of the LacO1 operator sequence. In some embodiments, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO: 24.

[0145] In some embodiments, the LacO operator comprised by the second nucleic acid construct comprises LacO1 and LacOid. In some embodiments, the LacOid is located downstream of LacO1. In some embodiments, the LacO operator comprises LacO1 and LacOid from 5' to 3' direction.

[0146] In certain embodiments, the promoter included in the second nucleic acid construct can be any promoter recognized by the RNA polymerase encoded by the RNAP gene included in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell. In certain embodiments, the promoter included in the second nucleic acid construct is selected from the T7 promoter, lac promoter, tac promoter, lacUV5 promoter of T7 phage.

[0147] In certain embodiments, the second nucleic acid construct comprises a plurality of target genes arranged in tandem. In certain embodiments, an additional promoter is optionally inserted between the plurality of target genes.

[0148] In certain embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein of the present invention. In certain embodiments, the promoter included in the first nucleic acid construct can be any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell. In certain embodiments, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter.

[0149] In some embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes of the same vector. In some embodiments, the vector is a plasmid based on pET-28a, the gene sequence originally encoding LacI in pET-28a is replaced with a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced with the LacO operator gene contained in the second nucleic acid construct.

[0150] In certain embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to darkness of the present invention. In such embodiments, the system for regulating the expression of the target gene is a dark-induced gene expression system, and the light-controlled repressor protein does not play a repressive role under dark conditions and allows the expression of the target gene, and preferably plays a repressive role under blue light (e.g., 430-495nm, such as 450-480nm) conditions and inhibits the expression of the target gene.

[0151] In certain embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to blue light of the present invention. In such embodiments, the system for regulating the expression of the target gene is a blue light-induced gene expression system, and the light-controlled repressor protein does not play a repressive role under blue light (e.g., 430-495nm, such as 450-480nm) conditions, and allows the expression of the target gene, and preferably plays a repressive role under dark conditions, and inhibits the expression of the target gene.

[0152] Reagent test kit

[0153] On the other hand, the present invention provides a kit comprising a host cell and an expression vector, wherein: the host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein of the present invention integrated into its genome; and the expression vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises the exogenous nucleotide sequence encoding the light-controlled repressor protein, and the second nucleic acid construct comprises a promoter, a LacO operator gene, and a cloning site for integrating a target gene (e.g., a multiple cloning site MCS).

[0154] In certain embodiments, the host cell is a prokaryotic cell. In certain embodiments, the host cell is an Escherichia coli. In certain embodiments, the host cell is an Escherichia coli having an exogenous nucleotide sequence encoding a light-controlled repressor protein integrated into its genome. In certain embodiments, the endogenous LacI gene of the Escherichia coli is destroyed. In certain embodiments, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence. In certain embodiments, the endogenous LacI gene of one copy of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the endogenous LacI gene of the other copy is knocked out.

[0155] In some embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes. In some embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter. In some embodiments, the vector is a plasmid based on pET-28a, and the gene sequence originally encoding LacI in pET-28a is replaced with a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced with the LacO operator gene contained in the second nucleic acid construct.

[0156] On the other hand, the present invention provides a kit comprising a host cell and an expression vector, wherein: the host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein of the present invention integrated into its genome; and the expression vector comprises the second nucleic acid construct.

[0157] In certain embodiments, the host cell is a prokaryotic cell. In certain embodiments, preferably, the host cell is Escherichia coli.

[0158] In certain embodiments, the host cell is an Escherichia coli having the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome. In certain embodiments, the endogenous LacI gene of the Escherichia coli is destroyed. In certain embodiments, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence. In certain embodiments, the endogenous LacI gene of one copy of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the endogenous LacI gene of the other copy is knocked out.

[0159] On the other hand, the present invention provides a kit comprising a host cell and an expression vector, wherein: the host cell has not integrated the exogenous nucleotide sequence encoding the light-controlled repressor protein into its genome; and the expression vector comprises the first nucleic acid construct and the second nucleic acid construct.

[0160] In certain embodiments, the host cell is a prokaryotic cell, such as E. coli.

[0161] In some embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes. In some embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter. In some embodiments, the vector is a plasmid based on pET-28a, and the gene sequence originally encoding LacI in pET-28a is replaced with a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced with the LacO operator gene contained in the second nucleic acid construct.

[0162] In certain embodiments, in the second nucleic acid construct described in any of the above aspects, the LacO operator gene is selected from LacO1, LacOid or a combination thereof.

[0163] In certain embodiments, in the second nucleic acid construct of any of the above aspects, the LacO operator comprises at least one copy (e.g., 1 to 8, such as 1, 2, 3, 4, 5, 6, 7, 8, such as 3 to 5) of the LacO1 operator sequence. In certain embodiments, the LacO operator comprises 3 to 5 copies of the LacO1 operator sequence. In certain embodiments, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO: 24.

[0164] In certain embodiments, in the second nucleic acid construct described in any of the above aspects, the LacO operator further comprises LacOid. In certain embodiments, the LacOid is located downstream of LacO1. In certain embodiments, the LacO operator comprises LacO1 and LacOid from 5' to 3' direction.

[0165] In certain embodiments, the second nucleic acid construct described in any of the above aspects, wherein the promoter is any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell; preferably selected from the T7 promoter of T7 phage, lac promoter, tac promoter, lacUV5 promoter.

[0166] In certain embodiments, the kit described in any of the above aspects is used to regulate the expression of a target gene.

[0167] In certain embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to darkness of the present invention. In such embodiments, the kit is used for dark-induced gene expression, i.e., it does not play a repressive role under dark conditions and allows the expression of the target gene, and preferably plays a repressive role and inhibits the expression of the target gene under blue light (e.g., 430-495nm, such as 450-480nm) conditions.

[0168] In certain embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to blue light of the present invention. In such embodiments, the kit is used for blue light-induced gene expression, i.e., it does not play a repressive role and allows the expression of the target gene under blue light (e.g., 430-495nm, such as 450-480nm) conditions, and preferably plays a repressive role and inhibits the expression of the target gene under dark conditions.

[0169] Method and application for regulating target gene expression

[0170] In another aspect, the present invention provides a light-controlled repressor protein, nucleic acid construct, vector, host cell, system, or kit of the present invention for use in regulating the expression of a target gene. The regulation of the expression of the target gene is carried out in vitro. The use is for non-therapeutic purposes.

[0171] The target gene involved in the present invention preferably encodes a target protein. There are no restrictions on the target protein. The target protein can be a polypeptide that does not naturally exist in the host cell, i.e., a heterologous protein, or can be natural to the host cell, i.e., a homologous protein of the host cell. The target protein involved in the present invention can be any peptide with biological activity, including but not limited to enzymes, regulatory proteins, receptors, hormones, cytokines, membrane proteins, transport proteins, antigens, vaccines, antigen-binding proteins, immunostimulatory proteins, allergens, antibodies or derivatives thereof. In certain embodiments, the target protein can be any protein suitable for the treatment or prevention of mammals (e.g., humans).

[0172] In addition, it is known to those skilled in the art that microorganisms can produce some important compounds through anabolism, so by regulating the anabolism pathway in the microbial cell, the amount of metabolite synthesis can be changed (such as increased). Therefore, the light-controlled repressor protein, nucleic acid construct, vector, host cell, system, or kit of the present invention can also be used to regulate microbial metabolic pathways. In some embodiments, the metabolic pathway can be endogenous or exogenous to Escherichia coli, including but not limited to the production pathway of 3-HP and 1,3-PDO. Therefore, in some embodiments, the target gene involved in the present invention also includes genes involved in compound biosynthesis or microbial anabolism pathways, thereby achieving regulation of compound biosynthesis or microbial metabolic pathways.

[0173] In another aspect, the present invention provides a method for regulating the expression of a target gene, comprising:

[0174] (1) providing the system for regulating the expression of a target gene of the present invention in a host cell;

[0175] (2) Cultivating the host cell under conditions that allow expression of the target gene and inducing expression of the target gene.

[0176] In certain embodiments, step (1) comprises: providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises an exogenous nucleotide sequence encoding the light-controlled repressor protein of the present invention integrated into its genome.

[0177] In certain embodiments, the host cell is a prokaryotic cell. In certain embodiments, the host cell is an Escherichia coli. In certain embodiments, the host cell is an Escherichia coli having an exogenous nucleotide sequence encoding a light-controlled repressor protein integrated into its genome. In certain embodiments, the endogenous LacI gene of the Escherichia coli is destroyed. In certain embodiments, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence. In certain embodiments, the endogenous LacI gene of one copy of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the endogenous LacI gene of the other copy is knocked out.

[0178] In some embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes. In some embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell, preferably selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter. In some embodiments, the vector is a plasmid based on pET-28a, and the gene sequence originally encoding LacI in pET-28a is replaced with a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced with the LacO operator gene contained in the second nucleic acid construct.

[0179] In certain embodiments, step (1) comprises: providing an expression vector comprising the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome.

[0180] In certain embodiments, the host cell is a prokaryotic cell. In certain embodiments, the host cell is an Escherichia coli. In certain embodiments, the host cell is an Escherichia coli having an exogenous nucleotide sequence encoding a light-controlled repressor protein integrated into its genome. In certain embodiments, the endogenous LacI gene of the Escherichia coli is destroyed. In certain embodiments, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence. In certain embodiments, the endogenous LacI gene of one copy of the Escherichia coli is replaced with the exogenous nucleotide sequence, and the endogenous LacI gene of the other copy is knocked out.

[0181] In certain embodiments, step (1) comprises: providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell does not contain the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome.

[0182] In certain embodiments, the host cell is a prokaryotic cell. In certain embodiments, the host cell is Escherichia coli.

[0183] In some embodiments, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes. In some embodiments, the first nucleic acid construct further comprises a promoter operably connected to the nucleotide sequence encoding the light-controlled repressor protein; preferably, the promoter is any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell, preferably selected from the wild-type LacI promoter, LacUV5 promoter, tac promoter, trc promoter. In some embodiments, the vector is a plasmid based on pET-28a, and the gene sequence originally encoding LacI in pET-28a is replaced with a nucleotide sequence encoding the light-controlled repressor protein of the present invention, and the original lac operon in pET-28a is replaced with the LacO operator gene contained in the second nucleic acid construct.

[0184] In certain embodiments, the step of introducing the expression vector into a host cell as described in any of the above embodiments can be performed by any means known in the art, such as transfection, transformation or transduction.

[0185] In certain embodiments, in the second nucleic acid construct described in any of the above embodiments, the LacO operator is selected from LacO1, LacOid or a combination thereof.

[0186] In some embodiments, the second nucleic acid construct described in any of the above embodiments, wherein the LacO operator gene comprises at least one copy (e.g., 1 to 8, such as 1, 2, 3, 4, 5, 6, 7, 8, such as 3 to 5) of the LacO1 operator sequence. In some embodiments, the LacO operator gene comprises 3 to 5 copies of the LacO1 operator sequence. In some embodiments, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO: 24.

[0187] In certain embodiments, in the second nucleic acid construct described in any of the above embodiments, the LacO operator further comprises LacOid. In certain embodiments, the LacOid is located downstream of LacO1. In certain embodiments, the LacO operator comprises LacO1 and LacOid from 5' to 3' direction.

[0188] In certain embodiments, the second nucleic acid construct described in any of the above embodiments, wherein the promoter is any promoter recognized by the RNA polymerase encoded by the RNAP gene contained in the host chromosome, that is, as long as it uses the RNA polymerase of the host cell, is preferably selected from the T7 promoter of T7 phage, lac promoter, tac promoter, lacUV5 promoter.

[0189] In some embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to darkness of the present invention; the induction conditions described in step (2) include: culturing the host cell under dark conditions to induce the expression of the target gene. In some embodiments, the method further includes culturing the recombinant host cell under blue light (e.g., 430-495nm, such as 450-480nm) to inhibit the expression of the target gene.

[0190] In some embodiments, the light-controlled repressor protein is selected from the light-controlled repressor protein responsive to blue light of the present invention; the induction conditions described in step (2) include: culturing the host cell under blue light (e.g., 430-495nm, such as 450-480nm) to induce the expression of the target gene. In some embodiments, the method further includes culturing the host cell under dark conditions to inhibit the expression of the target gene.

[0191] In certain embodiments, the blue light described herein refers to light with a wavelength between 430-495 nm (such as 450-480 nm). The blue light described herein can be emitted by a light source, including LED light panels, light strips, light tubes, and the like.

[0192] In certain embodiments, the expression vector comprising the first nucleic acid construct and the second nucleic acid construct can be obtained by the following steps: providing a vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a first nucleic acid construct, and the second expression cassette comprises a promoter, a LacO operator gene, and a cloning site (e.g., a multiple cloning site MCS) for integrating a target gene, and integrating the target gene into the cloning site to provide a recombinant expression vector integrated with the target gene.

[0193] In certain embodiments, the expression vector comprising the second nucleic acid construct can be obtained by the following steps: providing a vector comprising a promoter, a LacO operator, and a cloning site (e.g., a multiple cloning site MCS) for integrating a target gene, and integrating the target gene into the cloning site to provide a recombinant expression vector integrated with the target gene.

[0194] In certain embodiments, the method further comprises harvesting, isolating and / or purifying the expression product of the gene of interest (eg, a protein of interest).

[0195] Beneficial Effects

[0196] The novel light-controlled repressor protein OptoLacI provided by the present invention not only meets the requirements of single-component regulation of gene expression, but also can realize gene expression regulation with high temporal and spatial resolution, and has both blue light-induced and dark-induced systems. OptoLacI and the operating sequence form a modular light-controlled system, which can be used as soon as it is taken and has stronger system compatibility.

[0197] The present invention discloses a light-controlled gene expression system of Escherichia coli constructed based on a light-controlled repressor protein, and the system includes tool strains of various different induction strengths, and the induction system can adjust the expression intensity of the target gene by changing the frequency of blue light irradiation and the intensity of blue light. The blue light-induced gene expression system of the present invention exhibits extremely rigorous induction advantages, with very little expression leakage. The dark-induced gene expression system of the present invention has a good application effect in protein expression, and the induction effect is equivalent to the IPTG induction effect. The dark-induced gene expression system of the present invention has an excellent application effect in metabolic regulation, has a more rigorous regulation of metabolic pathways, and the target product synthesized by dark induction has a higher yield than the IPTG induction system. The dark-induced gene expression system of the present invention and the blue light-induced gene expression system both have excellent spatial rigor. Example

[0198] The invention is now described in the following non-limiting examples.

[0199] Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present application. The experimental methods in the embodiments are conventional methods unless otherwise specified. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0200] Example 1: Design of light-controlled repressor protein

[0201] In order to facilitate the screening of light-controlled repressor proteins, we used green fluorescent protein as a reporter gene. The restriction endonuclease sites at the 5' and 3' ends of green fluorescent protein were NheI and XhoI, respectively. The plasmid containing the GFP gene was amplified, and the plasmid containing the GFP gene and the pET-28a vector (purchased from Novagen) were directly digested with NheI and XhoI (Table 1), respectively. The pET-28a vector has a target transcription module (i.e., T7 promoter-lac operator-multiple cloning site) and contains a repressor gene lacI module; T4 DNA ligase was used for ligation (Table 2), and the ligation reaction system was transformed into competent cells DH5α and cultured at 37°C overnight. A single clone was picked for culture and sequencing the next day. The plasmid with correct sequencing was named pZH37, in which the GFP gene was inserted in the multiple cloning site.

[0202] Table 1 Double enzyme digestion system composition table (50μl)

[0203]

[0204] Table 2 T4 DNA ligation system components (10 μl)

[0205] Reagents Volume (μl) 10×T4DNA Ligase Reaction Buffer 1 TnsC(A225V) gene double restriction fragment (0.04pmol) X pGEX-6p-1 double restriction fragment (0.02pmol) Y T4DNA Ligase 1 <![CDATA[Add ddH2O]]> To 10

[0206] Compared with wild-type LacI, the introduction of mutation W220F in the repressor protein LacI W220F The repression ability was enhanced, and the IPTG-induced GFP leakage expression level was reduced by 10 times. Therefore, in order to construct a rigorous light-controlled gene expression system, LacI in the pZH37 plasmid was mutated to LacI W220F The mutated plasmid was named pZH49. In addition, the article reported the addition of the operator gene (LexA op ) can effectively increase the rigor of the light-controlled gene expression system, so the number of LacO1 genes in the lac operon part of the pZH37 plasmid was mutated to 3, and the mutated plasmid was named pZH39. At the same time, based on the pZH37 plasmid, the repressor gene lacI module was constructed as LacI W220F The mutant and lac operon part are plasmid pZH44 with 3*LacO1. Therefore, GFP was first used as a reporter gene to test the fluorescence intensity of plasmids pZH37, pZH49, pZH39 and pZH44 in BL21 (DE3) cells to provide a basic template for constructing a rigorous light-controlled gene expression system. Plasmids pZH37, pZH49, pZH39 and pZH44 were transformed into BL21 (DE3) competent cells, ice bathed for 30 minutes, heat shocked at 42°C for 90 seconds, ice bathed for 2 minutes, 900μl LB medium was added to the competent cells, incubated at 37°C constant temperature shaker for 1 hour, and an appropriate amount of bacterial liquid was spread on a solid LB plate containing kanamycin resistance, and cultured in a 37°C constant temperature incubator overnight. Single clones were picked the next day, and the effects of different plasmids on the stringency of IPTG induction were tested in liquid LB.

[0207] Compared with wild-type LacI, the W220F mutation reduced IPTG-induced expression leakage and increased GFP expression, indicating that LacI W220F It is beneficial to reduce IPTG-induced leaky expression. When three LacO1 manipulation genes are connected in series, the expression level of GFP remains unchanged, and the IPTG-induced leaky expression level remains almost unchanged. W220Fmutation and 3*LacO1 mutation, GFP expression level was not affected, while IPTG-induced GFP expression leakage was further reduced. Therefore, we also included LacI W220F and 3*LacO1 plasmid pZH44 as templates for photoswitchment.

[0208] The repressor protein LacI from Escherichia coli strain K12 consists of 360 amino acids. LacI molecules bind to each other to form a tetramer. The amino acid residues at positions 1-59 specifically bind to the operator gene, and the amino acids at positions 340-360 mediate the formation of the tetramer. Based on the principle of conformational changes of light-controlled elements and the structure of the repressor protein LacI (PDBID: 1LBG), through rational design, the light-controlled element LOV2 was inserted into the solvent-exposed loops, including loop1, loop2, and loop3. The amino acid sequence of the light-controlled element AsLOV2 (SEQ ID NO: 1) or its mutant cpLOV27 (SEQ ID NO: 2) was obtained by gene synthesis. The LOV2 gene was constructed into the LacI candidate loop site in pZH44 by the Gibson assembly method (Table 3). The Gibson assembly product was transformed into DH5α competent cells, ice-bathed for 30 min, heat-shocked at 42°C for 90 s, and then ice-bathed for 2 min. 900 μl of LB medium was added to the competent cells and incubated at 37°C in a constant temperature shaker for 1 h. An appropriate amount of bacterial solution was spread on a solid LB plate containing kanamycin resistance and cultured in a 37°C constant temperature incubator overnight.

[0209] Table 3 Gibson reaction components (10 μl)

[0210] Reagents Volume (μl) 5×CEⅡbuffer 2 Linearized pZH44 fragment (0.03 pmol) X Linearized LOV2 fragment (0.06 pmol) Y ExnaseⅡ 1 <![CDATA[ddH2O]]> To 10

[0211] The next day, single clones were picked and placed in LB medium containing kanamycin, cultured at 37°C in a constant temperature shaker for 8-9 hours, plasmids were extracted, and sent to a sequencing company for sequencing. The plasmids after successful sequencing were named pZH36, pZH46, pZH47, pZH48, pZH50, pZH51, pZH52, pZH53, pZH54, pZH55, pZH56, pZH57, pZH58, pZH62, pZH63, pZH64, and pZH65 (Table 4).

[0212] Table 4. Correspondence between LOV2 and cpLOV27 insertion positions and plasmid names

[0213]

[0214]

[0215] Example 2: Screening of light-controlled repressor proteins

[0216] In order to screen LacI mutants with optogenetic activity, pZH44 was used as a control plasmid, and 200 ng of the control plasmid and the test plasmid (Table 4) were transformed into BL21 (DE3) competent cells, ice bathed for 30 minutes, heat shocked at 42°C for 90 seconds, and ice bathed for 2 minutes. 900 μl of LB medium was added to the competent cells, incubated at 37°C constant temperature shaker for 1 hour, and an appropriate amount of bacterial liquid was spread on a solid LB plate containing kanamycin resistance, and cultured in a 37°C constant temperature incubator overnight. The next day, a single clone was picked into LB medium containing kanamycin, and cultured at 37°C constant temperature shaker for 12 hours. The bacterial liquid was transferred at an inoculation rate of 1%, and the strains containing the control plasmid and the test plasmid were transferred to two 24-well plates, and the 24-well plates were placed under blue light (90 μmol / m 2 / s) and cultured in the dark for 12 h. 1 mM IPTG was added to the control strain and induced for the same time in the dark. The green fluorescence intensity of different strains at 488 nm excitation wavelength and 530 nm emission wavelength, and the difference in GFP fluorescence value were then tested using an ELISA instrument to determine the light response activity of the LacI mutant.

[0217] Strains containing LacI mutant plasmids pZH47, pZH36, pZH48, pZH50, pZH51, pZH55, pZH56, pZH57, and pZH62 showed dark-induced GFP expression activity, among which the LacI mutant corresponding to pZH36 had better induction characteristics, with the highest dark-induced multiple and lower leakage expression; strains containing plasmids pZH63 and pZH58 showed blue-light induction activity, among which the mutant corresponding to pZH58 had more significant blue-light induction activity ( Figure 1 ). The vector thus obtained containing the target transcription module and the light-controlled repressor protein gene is called a light-controlled vector.

[0218] Example 3: Construction of light-controlled Escherichia coli strains

[0219] pZH36 corresponding to the mutant LacI M9 (OptoLacI D ) has dark-responsive activity, while the mutant LacI corresponding to pZH58 M1 (OptoLacI L ) has activity in response to blue light. D 、OptoLacI LWe constructed light-controlled E. coli strains. First, we used BL21(DE3) as the starting strain. The BL21(DE3) genome contains two copies of wild-type LacI. We selected 500bp of wild-type LacI upstream and downstream as homology arms and linked the homology arms to OptoLacI. D The genes were co-constructed into the Donor plasmid, and the plasmids were named pZH76 and pZH78. On the plasmid containing the Cas9 protein gene, a plasmid containing two N20s was constructed, and the plasmid was named pZH83. D The wild-type LacI site was integrated into the genome of BL21(DE3), and two OptoLacI sites were integrated into the upstream and downstream LacI sites of the genome. D The strain was named BL21_Dark_D V1 , while the upstream LacI of the genome was knocked out and the downstream LacI was replaced by OptoLacI D The strain was named BL21_Dark_S V1 The same method was used to construct the Donor plasmids pZH77 and pZH79, the targeting plasmid was pZH84, and the blue light responsive mutant OptoLacI was used to construct the L , construct an E. coli strain that responds to blue light, and insert OptoLacI L The wild-type LacI site was integrated into the genome of BL21(DE3), and two OptoLacI sites were integrated into the upstream and downstream LacI sites of the genome. L The strain was named BL21_Light_D, and the upstream LacI of the genome was knocked out and the downstream LacI was replaced by OptoLacI L The strain was named BL21_Light_S ( Figure 2 ). The strain obtained in this way, in which the light-controlled repressor protein gene is integrated into the genome, is called a light-controlled strain.

[0220] Example 4: Performance test of light-controlled Escherichia coli expressing dark-induced genes

[0221] In order to test the performance of the strain for dark-induced gene expression and optimize the effect of different numbers of LacO1 in series on the plasmid on its light-controlled performance, we constructed plasmids with different numbers of LacO1 in series (Table 5). The repressor gene modules of each plasmid were mutant LacI. M9 These plasmids were transformed into dark-induced light-controlled strains, cultured in a blue light environment, and then transferred to 24-well plates at a 1% inoculation rate to induce GFP expression under dark conditions.

[0222] Table 5 Correspondence between dark inducible system plasmids and different numbers of LacO1

[0223] Plasmid name Number of LacO1 series pZH91 1 pZH96 2 pZH36 3 oeLh 4

[0224] The results are as follows Figure 3 As shown, in the dark-induced light-controlled strain BL21_Dark_S, as the number of LacO1 tandems on the plasmid increased, the stringency of dark-induced GFP expression showed an increasing trend, among which 3*LacO1 and 4*LacO1 had the same induction multiple ( Figure 3 A) In the dark-induced light-controlled strain BL21_Dark_D V1 In the experiment, as the number of LacO1 tandems on the plasmid increased, the stringency of dark-induced GFP expression showed an increasing trend, with 3*LacO1 and 4*LacO1 having the same induction multiple ( Figure 3 B).

[0225] Example 5: Performance test of light-controlled Escherichia coli with blue light-induced gene expression

[0226] In order to test the performance of strains that can induce gene expression by blue light and optimize the effect of different numbers of LacO1 in series on plasmids on their light control performance, we successively constructed plasmids with different numbers of LacO1 in series on plasmids (Table 6). The repressor gene modules of each plasmid were mutant LacI. M1 These plasmids were transformed into blue light-induced light-controlled strains, cultured in a dark environment, and then transferred to 24-well plates at a 1% inoculation rate to induce GFP expression under blue light conditions.

[0227] Table 6 Correspondence between blue light inducible system plasmids and different numbers of LacO1

[0228] Plasmid name Number of LacO1 series pZH251 1 pZH259 2 pZH260 3 pZH261 4

[0229] The results are as follows Figure 4 As shown, in the blue light-induced light-controlled strain BL21_Light_S, as the number of LacO1 tandems on the plasmid increased, the stringency of blue light-induced GFP expression showed an increasing trend, among which 3*LacO1 and 4*LacO1 had the same induction multiple ( Figure 4 A). In the blue light-controlled strain BL21_Light_D, as the number of LacO1 tandems on the plasmid increased, the stringency of blue light-induced GFP expression showed an increasing trend, where the induction multiples of 3*LacO1 and 4*LacO1 were the same ( Figure 4 B).

[0230] Example 6: Optimization of the induction intensity of the dark-induced gene expression system

[0231] In metabolic engineering and industrial production, the dark-induced system has a higher application potential. However, the current dark-induced gene expression system has the problem of low induction intensity. Therefore, we optimized the induction intensity of the dark-induced gene expression system. By saturating the key amino acid sites of LacI, we screened mutants with enhanced induction intensity. After mutating it into different mutants, the induction intensity increased by 2.9 to 6.9 times. When the lysine at position 84 of this site was mutated to glutamic acid, its induction intensity was higher than that of LacI. W220F Increased by about 6.5 times ( Figure 5 ). Therefore, based on this, we obtained the second generation of light-controlled repressor protein OptoLacI DV2 (SEQ ID NO: 29), BL21_Dark_S V1 With BL21_Dark_D V1 The site on the genome was mutated to obtain the second version of the dark-induced gene expression strain BL21_Dark_S V2 With BL21_Dark_D V2 .

[0232] Example 7: Effects of different promoters on the dark-induced gene expression system

[0233] In order to test the performance of the strain for dark-induced gene expression and characterize the effects of different promoters on the plasmid on its light-controlled performance, we constructed plasmids containing different promoters (T7, tac, lac, lacUV5) on the plasmid, and the repressor gene module of each plasmid was mutant LacI. M9-K84E These plasmids were transformed into the dark-induced light-controlled strain BL21_Dark_D V1 The cells were cultured in a blue light environment and then transferred to a 24-well plate at a 1% inoculum to induce GFP expression in the dark. Figure 6 As shown, in the dark-induced light-controlled strain BL21_Dark_D V1 In the experiment, for plasmids carrying different promoters, the dark-induced GFP expression levels were similar, but the rigor of dark-induced GFP expression was different. This experimental result proves that T7, tac, lac, and lacUV5 promoters are all suitable for dark-induced gene expression systems.

[0234] Example 8: Optimization of the induction multiple of the dark-induced gene expression system

[0235] In BL21_Dark_D V2On this basis, by optimizing the number of LacO1 tandems (1-8), we continued to optimize the induction multiple of the dark-induced gene expression system, gradually increased the number of LacO1 tandems on the plasmid pZH36, and transformed it into BL21_Dark_D V2 The strain was cultured under blue light, and then transferred to a 24-well plate at a 1% inoculation rate to induce GFP expression in the dark. The results showed that the best induction multiple was obtained when 4*LacO1(pML308) was tandemly linked to the plasmid ( Figure 7 A). At the same time, a series of plasmids were constructed based on the mutant LacOid (SEQ ID NO: 25) of LacO1 on plasmid pZH36 to test their dark induction effects. The results showed that the use of LacO1 and LacOid in series still had a good dark induction effect, and the overall expression level was increased ( Figure 7 B).

[0236] Example 9: Application of Dark-Inducible Gene Expression System in Protein Expression

[0237] In metabolic engineering practice, the light-controlled system for dark-induced protein production has significant advantages over the light-controlled system for blue-light-induced protein production. Therefore, we explored the application of the dark-induced gene expression system in protein expression. Taking glucose dehydrogenase (GDH, accession number: P40288), PET degrading enzyme PETase (accession number: A0A0K8P0E4) and alkaline protease (accession number: P00780) as examples, the expression of different genes by the light-controlled system for dark-induced production was tested (Table 7). The plasmids corresponding to the above-mentioned target proteins are pML333, pML351, and pML353, respectively. Among them, the number of LacO1 in the target transcription module is 4, and the light-controlled repressor protein module is OptoLacI. DV2 .

[0238] Table 7 Summary of application information of dark-induced gene expression system in protein expression

[0239] Protein and theoretical molecular weight Plasmid name Expression strain alkalineprotease (36.8KD) pML333 <![CDATA[BL21_Dark_D V2 ]]> PETase (29.0KD) pML351 <![CDATA[BL21_Dark_D V2 ]]> GDH (29.4KD) pML353 <![CDATA[BL21_Dark_D V1 ]]>

[0240] Take 200 ng of plasmid and transform it into BL21_Dark_D V1 or BL21_Dark_D V2 Competent cells were placed in an ice bath for 30 min, heat-shocked at 42 °C for 90 s, and placed in an ice bath for 2 min. 900 μl of LB medium was added to the competent cells and incubated at 37 °C for 1 h in a light-controlled shaker with a blue light intensity of 90 μmol / m 2 / s, take an appropriate amount of bacterial solution and spread it on a solid LB plate containing kanamycin resistance, and culture it overnight in a 37℃ blue light incubator (blue light intensity is 80μmol / m2 / s). The next day, pick a single clone and put it into LB medium containing kanamycin, and culture it in a 37℃ light-controlled shaker for 12h. Transfer the bacterial solution to a 24-well plate with an inoculation volume of 1%, and place the 24-well plate in a blue light incubator (80μmol / m 2 / s), cultured to OD600 = 0.1-0.8, covered the 24-well plate with tin foil, dark induced, and sampled at 0h, 2h, 4h, 6h, 9h, and 12h. The samples at different time points were centrifuged at 12000rpm for 3min, the LB medium was removed, the cells were resuspended with PBS, an appropriate amount of SDS-PAGE loading buffer was added to the resuspended bacterial solution, boiled at 100℃ for 20min, and 2μl of the sample was taken for 12% SDS-PAGE identification, and the light control effect of dark-induced gene expression was identified by SDS-PAGE.

[0241] The research results are as follows Figure 8 As shown, Figure A is GDH, Figure B is PETase, and Figure C is alkalineprotease. As the dark induction time increases, the target protein band gradually thickens, the target protein band is obvious and clear, and there is very little expression leakage before dark induction (0h), indicating that the dark-inducible gene expression system has a good application effect in protein expression.

[0242] Example 10: Application of blue light-induced gene expression system in protein expression

[0243] In order to characterize the induction characteristics of the blue light-induced gene expression system, we also explored the application of the blue light-induced gene expression system in protein expression. Taking acetyl-CoA C-acyltransferase (FadA) (accession number: A4XSM9) and malate dehydrogenase (MdhII) (accession number: D9PVI7) as examples, the expression of different genes by the light-controlled system induced by blue light was tested (Table 8). The plasmids corresponding to the above target proteins are pML359 and pML361, respectively. The number of LacO1 in the target transcription module is 1, and the light-controlled repressor protein module is LacI. M1 .

[0244] Table 8 Summary of application information of blue light-induced gene expression system in protein expression

[0245] Protein and theoretical molecular weight Plasmid name Expression strain FadA (41.6KD) pML359 BL21_Light_D MdhII (35.9KD) pML361 BL21_Light_D

[0246] Take 200 ng of plasmid and transform it into BL21_Light_D competent cells, place it on ice for 30 min, heat shock it at 42°C for 90 s, place it on ice for 2 min, add 900 μl of LB medium to the competent cells, and incubate it at 37°C for 1 h in a light-controlled shaker with a blue light intensity of 80 μmol / m 2 / s, take an appropriate amount of bacterial solution and apply it to the solid LB plate containing kanamycin resistance, and culture it in a 37℃ incubator overnight. The next day, pick a single clone to LB medium containing kanamycin and culture it in a shaking incubator at 37℃ for 12h. Transfer the bacterial solution to a 24-well plate at a 1% inoculation volume, cover the 24-well plate with tin foil, culture the 24-well plate to OD600 = 0.1-0.8, and place it under blue light (80μmol / m 2 / s) for 9h of induction. Samples at different time points were centrifuged at 12000 rpm for 3 min, the LB medium was removed, the cells were resuspended with PBS, an appropriate amount of SDS-PAGE loading buffer was added to the resuspended bacterial solution, boiled at 100°C for 20 min, 2 μl of the sample was taken for 12% SDS-PAGE identification, and the light-controlled effect of dark-induced gene expression was identified by SDS-PAGE.

[0247] The research results are as follows Fig. 9 As shown, Figure A is FadA and Figure B is MdhII. The target protein bands in the blue light induced group are obvious and clear, while no obvious protein bands are found in the corresponding positions of the dark control group, indicating that the blue light induced gene expression system has very little expression leakage in protein expression and has a good application effect.

[0248] Example 11: Application of Dark-Inducible Gene Expression System in 1,3-Propanediol Production

[0249] In the practice of metabolic engineering, it is a major challenge to resolve the contradiction between the demand for culture matrix for host cell growth and target product production. Compared with the light-controlled system for blue light-induced protein production, the light-controlled system for dark-induced protein production is more rigorous and can effectively control the distribution of metabolic flux by controlling the expression of key enzymes. Therefore, we explored the application of the dark-induced gene expression system in metabolic flux control. Taking 1,3-propanediol as an example, the control of the metabolic flux of the 1,3-propanediol biosynthesis pathway by the light-controlled system of dark-induced production was tested.

[0250] First, glycerol dehydratase (dhaB1234, gene sequence see SEQ ID NO: 20) and glycerol dehydratase reactivating enzyme (gdrAB, gene sequence see SEQ ID NO: 21, SEQ ID NO: 22) were cloned from the genome of Klebsiella pneumoniae, and alcohol dehydrogenase (yqhD, gene sequence see SEQ ID NO: 23) was cloned from the genome of Escherichia coli MG1655. They were cloned into the expression vector pCDFDuet (purchased from Novagen) to construct the recombinant plasmid pCDFDuet-dhaB1234-gdrB-yqhD-gdrA (see Fig.10 As shown, the expression cassette of the key gene of 1,3-propanediol biosynthesis), the pCDFDuet-1 vector contains T7 promoter and lac operator sequence.

[0251] Transformed into BL21(DE3) and BL21_Dark_D v1 The 1,3-propanediol producing strains BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA and BL21_Dark_D v1 / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA. Specifically, 200 ng of plasmid was transformed into BL21_Dark_D V1 Or BL21(DE3) competent cells, ice bath for 30 min, heat shock at 42°C for 90 s, ice bath for 2 min, add 900 μl LB medium to the competent cells. The host cell is BL21_Dark_D V1 The cells were incubated at 37°C in a light-controlled shaker for 1 h with a blue light intensity of 90 μmol / m 2 / s; host cells are BL21 (DE3) and directly revived in the dark for 1 hour. Take an appropriate amount of bacterial solution and spread it on a solid LB plate containing kanamycin resistance. The host cells are BL21_Dark_D V1 The host cells were incubated in a 37°C blue light incubator (blue light intensity was 80 μmol / m2 / s), and the host cells were BL21(DE3) in a 37°C incubator for overnight culture. The fermentation comparison experiment was carried out according to Table 8. For BL21_Dark_D V1 / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA, pick a single clone and transfer it to LB medium containing kanamycin, and culture it in a light-controlled shaker at 37°C for 12-18 hours as a seed solution. Transfer the bacterial solution to a 24-well plate at a 1% inoculation volume, and place the 24-well plate under blue light (80 μmol / m 2 / s), and cultured until OD 600=0.1~0.6, one group used tin foil to cover the 24-well plate completely, dark induction, and the other group was still cultured under blue light, and samples were taken after fermentation for 48 hours. For BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA, a single clone was picked and transferred to LB medium containing kanamycin, and cultured at 37℃ shaking for 12-18 hours as seed liquid. The bacterial liquid was transferred to a 24-well plate at an inoculation rate of 1%, and the 24-well plate was placed under blue light (80μmol / m 2 / s), and cultured until OD 600 =0.1-0.6, one group was added with IPTG to induce 1,3-PDO synthesis, and the other group was not added with IPTG, and samples were taken after fermentation for 48 hours. 800 μL of fermentation liquid was taken, centrifuged at 12000 rpm, and the supernatant was taken to detect the 1,3-PDO yield using the HPLC method reported in the literature.

[0252] Table 8 Fermentation comparison test design

[0253]

[0254] The research results are as follows Fig.11 As shown in the figure, compared with the common BL21(DE3) using IPTG to control the metabolic pathway flux of 1,3-propylene glycol, there was no significant difference between the induced group and the uninduced group; the dark-induced expression system was more rigorous, and the induced group had a significantly higher 1,3-propylene glycol yield than the uninduced group, and BL21_Dark_D v1 The 1,3-propanediol production of the BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA induced group was significantly higher than that of the BL21(DE3) / pCDFDuet-dhaB1234-gdrB-yqhD-gdrA group, indicating that the dark-induced gene expression system has a good application effect in metabolic flux control.

[0255] The above results show that: (1) By inserting light-controlled elements (LOV2 and its mutants) into the target protein sequence, light-controlled protein function can be achieved. (2) The Escherichia coli light-controlled gene expression system developed based on the light-controlled repressor protein OptoLacI can be applied to protein production. The inducer is dark conditions or blue light irradiation. The induction cost is low and the induction operation is fast, which has great advantages in protein production. (3) The Escherichia coli light-controlled gene expression system developed based on the light-controlled repressor protein OptoLacI can be applied to the production of dynamically regulated chemicals. (4) Light-controlled expression can be achieved by providing a light-controlled vector in a light-controlled strain, providing a common expression vector in a light-controlled strain, and providing a light-controlled vector in a common strain.

[0256] Example 12: Comparison of the OptoLacI system and the IPTG induction system

[0257] The plasmid pML308 expressing the dark-induced gene was transformed into the light-controlled strain BL21_Dark_D V1 and BL21_Dark_D V2 The single clone was picked and cultured overnight under blue light. The next day, it was transferred to a 24-well plate with a 1% inoculum, placed in a dark environment, and cultured at 37°C for 12 hours. The GFP fluorescence intensity was detected. The plasmid pZH251 for blue light-induced gene expression was transformed into the light-controlled strain BL21_Light_D, and a single clone was picked and cultured overnight under dark conditions. The next day, it was inoculated into a 24-well plate with a 1% inoculum, placed in a blue light environment, and cultured at 37°C for 9 hours. The GFP fluorescence intensity was detected. At the same time, pZH37 was transformed into BL21(DE3), a single clone was picked, and cultured until OD 600 =0.5, add 1 mM IPTG, induce at 37°C for 12 h, and detect the fluorescence intensity of GFP.

[0258] The results are as follows Fig.12 As shown, although the expression intensity of the dark-induced gene expression system and the blue-light-induced gene expression system is lower than the IPTG-induced intensity, in terms of induction multiples, the induction multiples of the blue-light-induced gene expression system are as high as 75 times, while the induction multiples of the IPTG-induced system are only 16 times, indicating that the blue-light-induced system has a more rigorous induction feature and can avoid unnecessary expression leakage. In addition, the dark-induced gene expression system and the blue-light-induced gene expression system of the present invention have stronger adjustability, and the protein expression amount and leakage expression can be controlled by adjusting the blue light pulse mode and the blue light intensity, while the IPTG system does not have this feature.

[0259] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Those skilled in the art will understand that various modifications and changes can be made to the details based on all the teachings published, and these changes are within the scope of protection of the present invention. The entire invention is given by the attached claims and any equivalents thereof.

[0260] Sequence information

[0261] SEQ ID NO:1 (AsLOV2)

[0262] LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGNRNCRFLQGPETDRATVRKIRDAIDNQTEV

[0263] TVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENID

[0264] EAA

[0265] SEQ ID NO:2(cpLOV27)

[0266] REGVMLIKKTAENIDEAAKELGGGSGGSLATTLERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSRE

[0267] EILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQ

[0268] YFIGVQLDGTEHVRDAAE

[0269] SEQ ID NO:3(LacI M1 )

[0270] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0271] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0272] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0273] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0274] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQ LERIEKNFVITDP

[0275] RLPDNPIIFASDSFLQLTEYSREEILGNRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTKSG

[0276] KKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA AVKGNQL

[0277] LPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0278] SEQ ID NO:4(LacI M2 )

[0279] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0280] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0281] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0282] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0283] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQA LERIEKNFVITD

[0284] PRLPDNPIIFASDSFLQLTEYSREEILGNRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTKSG

[0285] KKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA VKGNQLL

[0286] PVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0287] SEQ ID NO:5(LacI M3 )

[0288] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0289] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0290] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0291] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0292] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAV LERIEKNFVIT

[0293] DPRLPDNPIIFASDSFLQLTEYSREEILGNRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTKS

[0294] GKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA KGNQLL

[0295] PVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0296] SEQ ID NO:6(LacI M4 )

[0297] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0298] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0299] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0300] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0301] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVK LERIEKNFVI

[0302] TDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTK

[0303] SGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA GNQLL

[0304] PVSLVKRCTTLAPNTQTASPRADSLMQLARQVSRLESGQ

[0305] SEQ ID NO:7(LacI M5 )

[0306] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0307] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0308] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0309] RRLLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0310] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKG LERIEKNF

[0311] VITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINY

[0312] TKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA NQL

[0313] LPVSLVKRCTTLAPNTQTASPRADSLMQLARQVSRLESGQ

[0314] SEQ ID NO:8(LacI M6 )

[0315] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0316] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0317] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0318] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0319] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGN LEADERSHIP

[0320] FVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLIN

[0321] YTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGVMLIKKTAENIDEAA QL

[0322] LPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0323] SEQ ID NO:9(LacI M7 )

[0324] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0325] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0326] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0327] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0328] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0329] VKRKTTLAPN LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRK

[0330] IRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREGV

[0331] MLIKKTAENIDEAA TQTASPRALADSLMQLARQVSRLESGQ

[0332] SEQ ID NO:10(LacI M8 )

[0333] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0334] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0335] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0336] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0337] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0338] VKRKTTLAPNT LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVR

[0339] KIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAEREG

[0340] VMLIKKTAENIDEAA QTASPRALADSLMQLARQVSRLESGQ

[0341] SEQ ID NO:11(LacI M9 )

[0342] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0343] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0344] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALAGPLSSVSA

[0345] RLRLAGWHKYLTRNQIQPIAERGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0346] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0347] VKRKTTLAPNTQ LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATV

[0348] RKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAERE

[0349] GVMLIKKTAENIDEAA TASPRALADSLMQLARQVSRLESGQ

[0350] SEQ ID NO:12(LacI M10 )

[0351] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0352] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0353] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALAGPLSSVSA

[0354] RLRLAGWHKYLTRNQIQPIAERGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0355] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0356] VKRKTTLAPNTQT LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRAT

[0357] VRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAER

[0358] EGVMLIKKTAENIDEAA ASPRALADSLMQLARQVSRLESGQ

[0359] SEQ ID NO:13(LacI M11 )

[0360] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0361] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0362] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0363] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0364] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0365] VKRKTTLAPNTQTA LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRA

[0366] TVRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAE

[0367] REGVMLICKTAENIDEAA SPRALADSLMQLARQVSRLESGQ

[0368] SEQ ID NO:14(LacI M12 )

[0369] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0370] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0371] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0372] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0373] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0374] VKRKTTLAPNTQTAS LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDR

[0375] ATVRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAA

[0376] EREGVMLIKKTAENIDEAA PRALADSLMQLARQVSRLESGQ

[0377] SEQ ID NO:15(LacI M13 )

[0378] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0379] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0380] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0381] RLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0382] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0383] VKRKTTLAPNTQTASP LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETD

[0384] RATVRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDA

[0385] AEREGVMLIKKTAENIDEAA RALADSLMQLARQVSRLESGQ

[0386] SEQ ID NO:16(LacI M14 )

[0387] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0388] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0389] DDQDAIAVEAACTNVPALFLDVSD REGVMLIKKTAENIDEAAKELGGGGSGGSLATTLERIEKNFV

[0390] ITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYT

[0391] KSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAE QTPINSIIFSHEDGTRLGVEHLV

[0392] ALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPT

[0393] AMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLL

[0394] QLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0395] SEQ ID NO:17(LacI M15 )

[0396] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0397] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0398] DDQDAIAVEAACTNVPALFLDVSDQ REGVMLIKKTAENIDEAAKELGGGSGGSLATTLERIKNF

[0399] VITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINY

[0400] TKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAE TPINSIIFSHEDGTRLGVEHLVA

[0401] LGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPTA

[0402] MLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQ

[0403] LSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0404] SEQ ID NO:18(LacI M16 )

[0405] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0406] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0407] DDQDAIAVEAACTNVPALFLDVSDQT REGVMLIKTAENIDEAAKELGGGGSGGSLATTLERIEKN

[0408] FVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLIN

[0409] YTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAE PINSIIFSHEDGTRLGVEHLV

[0410] ALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPT

[0411] AMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLL

[0412] QLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0413] SEQ ID NO:19 (LacI M17 )

[0414] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0415] IGVATSSLALHAPSQIVAAIKSRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0416] DDQDAIAVEAACTNVPALFLDVSDQTP REGVMLIKTAENIDEAAKELGGGGSGGSLATTLERIEK

[0417] NFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATVRKIRDAIDNQTEVTVQLI

[0418] NYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAE INSIIFSHEDGTRLGVEHLV

[0419] ALGHQQIALLAGPLSSVSARLRLAGWHKYLTRNQIQPIAEREGDFSAMSGFQQTMQMLNEGIVPT

[0420] AMLVANDQMALGAMRAITESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLL

[0421] QLSQGQAVKGNQLLPVSLVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0422] SEQ ID NO:20 (Glycerol dehydratase dhaB1234)

[0423] MKRSKRFAVLAQRPVNQDGLIGEWPEEGLIAMDSPFDPVSSVKVDNGLIVELDGKRRDQFDMID

[0424] RFIADYAINVERTEQAMRLEAVEIARMLVDIHVSREEIIAITTAITPAKAVEVMAQMNVVEMMMA

[0425] LQKMRARRTPSNQCHVTNLKDNPVQIAADAAEAGIRGFSEQETTVGIARYAPFNALALLVGSQC

[0426] GRPGVLTQCSVEEATELELGMRGLTSYAETVSVYGTEAVFTDGDDTPWSKAFLASAYASRGLK

[0427] MRYTSGTGSEALMGYSESKSMLYLESRCIFITKGAGVQGLQNGAVSCIGMTGAVPSGIRAVLAEN

[0428] LIASMLDLEVASANDQTFSHSDIRRTARTLMQMLPGTDFIFSGYSAVPNYDNMFAGSNFDAEDFD

[0429] DYNILQRDLMVDGGLRPVTEAETIAIRQKAARAIQAVFRELGLPPIADEEVEAATYAHGSNEMPP

[0430] RNVVEDLSAVEEMMKRNITGLDIVGALSRSGFEDIASNILNMLRQRVTGDYLQTSAILDRQFEVV

[0431] SAVNDINDYQGPGTGYRISAERWAEIKNIPGVVQPDTIEVQQTTQIQPSFTLKTREGGVASADERA

[0432] DEVVIGVGPAFDKHQHHTLIDMPHGAILKELIAGVEEEGLHARVVRILRTSDVSFMAWDAANLSG

[0433] SGIGIGIQSKGTTVIHQRDLLPLSNLELFSQAPLLTLETYRQIGKNAARYARKESPSPVPVVNDQMV

[0434] RPKFMAKAALFHIKETKHVVQDAEPVTLHVDLVREMSEKTMRVQDYPLATRCPEHILTPTGKPL

[0435] TDITLEKVLSGEVGPQDVRISCQTLEYQAQIAEQMQRHAVARNFRRAAELIAIPDERILAIYNALRPFRSSQAELLAIADELEHTWHATVNAAFVRESAEVYQQRHKLRKGS*

[0436] SEQ ID NO:21 (Glycerol dehydratase reactivase gdrA)

[0437] MPLIAGIDIGNATTEVALASDDPQARAFVASGIVATTGMKGTRDNIAGTLAALEQALAKTPWSMS

[0438] DVSRIYLNEAAPVIGDVAMETITETIITESTMIGHNPQTPGGVGVGVGTTIALGRLATLPAAQYAE

[0439] GWIVLIDDAVDFLDAVWWLNEALDRGINVVAAILKKDDGVLVNNRLRKTLPVVDEVTLLEQVP

[0440] EGVMAAVEVAAPGQVVRILSNPYGIATFFGLSPEETQAIVPIARALIGNRSAVVLKTPQGDVQSRV

[0441] IPAGNLYISGEKRRGEADVAEGAEAIMQAMSACAPVRDIRGEPGTHAGGMLERVRKVMASLTDH

[0442] EMSAIYIQDLLAVDTFIPRKVQGGMAGECAMENAVGMAAMVKADRLQMQVIARELSARLQTEV

[0443] VVGGVEANMAIAGALTTPGCAAPLAILDLGAGSTDAAIVNAEGQITAVHLAGAGNMVSLLIKTE

[0444] LGLEDLSLAEAIKKYPLAKVESLFSIRHENGAVEFFREALSPAVFAKVVYIKEGELVPIDNASPLEK

[0445] IRLVRRQAKEKVFVTNCLRALRQVSPGGSIRDIAFVVLVGGSSLDFEIPQLITEALSHYGVVAGQGNIRGTEGPRNAVATGLLLAGQAN*

[0446] SEQ ID NO:22(Glycerol dehydratase reactivating enzyme gdrB)

[0447] MSLSPPGVRLFYDPRGHHAGAINELCWGLEEQGVPCQTITYDGGGDAAALGALAARSSPLRVGI GLSASGEIALTHAQLPADAPLATGHVTDSDDHLRTLGANAGQLVKVLPLSERN*

[0448] SEQ ID NO:23(Alcohol dehydrogenase yqhD)

[0449] MNNFNLHTPTRILFGKGAIAGLREQIPHDARVLITYGGGSVKKTGVLDQVLDALKGMDVLEFGGI

[0450] EPNPAYETLMNAVKLVREQKVTFLLAVGGGSVLDGTKFIAAAANYPENIDPWHILQTGGKEIKSA

[0451] IPMGCVLTLPATGSESNAGAVISRKTTGDKQAFHSAHVQPVFAVLDPVYTYTLPPRQVANGVVD

[0452] AFVHTVEQYVTKPVDAKIQDRFAEGILLTLIEDGPKALKEPENYDVRANVMWAATQALNGLIGA

[0453] GVPQDWATHMLGHELTAMHGLDHAQTLAIVLPALWNEKRDTKRAKLLQYAERVWNITEGSDD

[0454] ERIDAAIAATRNFFEQLGVPTHLSDYGLDGSSIPALLKKLEEHGMTQLGENHDITLDVSRRIYEAAR*

[0455] SEQ ID NO:24(LacO1 operator sequence)

[0456] GGAATTGTGAGCGGATAACAATTCC

[0457] SEQ ID NO:25 (LacOid operator sequence)

[0458] AATTgtgagcgcTCAcaatt

[0459] SEQ ID NO:26 (LacI WT repressor protein)

[0460] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0461] IGVATSSLALHAPSQIVAAI K SRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0462] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0463] RLRLAGWHKYLTRNQIQPIAEREGD W SAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRA

[0464] ITESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVS

[0465] LVKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0466] SEQ ID NO:27 (LacI W220F repressor protein)

[0467] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0468] IGVATSSLALHAPSQIVAAI K SRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0469] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0470] RLRLAGWHKYLTRNQIQPIAEREGD F SAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0471] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0472] VKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0473] SEQ ID NO:28(LacI W220F+K84E Operator protein)

[0474] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0475] IGVATSSLALHAPSQIVAAI E SRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0476] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALLAGPLSSVSA

[0477] RLRLAGWHKYLTRNQIQPIAEREGD F SAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0478] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0479] VKRKTTLAPNTQTASPRALADSLMQLARQVSRLESGQ

[0480] SEQ ID NO:29(OptoLacI DV2 )

[0481] VKPVTLYDVAEYAGVSYQTVSRVVNQASHVSAKTREKVEAAMAELNYIPNRVAQQLAGKQSLL

[0482] IGVATSSLALHAPSQIVAAI E SRADQLGASVVVSMVERSGVEACKAAVHNLLAQRVSGLIINYPL

[0483] DDQDAIAVEAACTNVPALFLDVSDQTPINSIIFSHEDGTRLGVEHLVALGHQQIALAGPLSSVSA

[0484] RLRLAGWHKYLTRNQIQPIAEREGD F SAMSGFQQTMQMLNEGIVPTAMLVANDQMALGAMRAI

[0485] TESGLRVGADISVVGYDDTEDSSCYIPPLTTIKQDFRLLGQTSVDRLLQLSQGQAVKGNQLLPVSL

[0486] VKRKTTLAPNTQ LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETDRATV

[0487] RKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQYFIGVQLDGTEHVRDAAERE

[0488] GVMLIKKTAENIDEAA TASPRALADSLMQLARQVSRLESGQ

[0489] SEQ ID NO: 30

[0490] MLDMGQDRPIDGSGAPGADDTRVEVQPPAQWVLDLIEASPIASVVSDPRLADNPLIAINQ

[0491] AFTDLTGYSEEECVGRNCRFLAGSGTEPWLTDKIRQGVREHKPVLVEILNYKKDGTPFRN

[0492] AVLVAPIYDDDDELLYFLGSQVEVDDDQPNMGMARRRERAAEMLKTLSPRQLEVTTLVASG

[0493] LRNKEVAARLGLSEKTVKMHRGLVMEKLNLKTSADLVRIAVEAGI

[0494] SEQ ID NO:31 (Photosensitive domain LOV2 from Arabidopsis thaliana)

[0495] GSPEFIEKNFVISDPRLPDNPIIFASDSFLELTEYSREEILGRNCRFLQGPETDQATVQKIRDAIRDQR

[0496] EITVQLINYTKSGKKFWNLFHLQPMRDQKGELQYFIGVQLDGSDHV

Claims

1. A light-controlled repressor protein comprising a LacI protein and a LOV domain inserted between adjacent amino acids in the Loop-1, Loop-2 or Loop-3 region of the LacI protein.

2. The light-controlled repressor protein according to claim 1, wherein The LOV domain is a LOV2 domain; Preferably, the LOV domain is selected from the LOV2 domain (AsLOV2) of the oat phytochrome 1 gene, the photosensitive protein EL222 from Staphylococcus australis, the photosensitive domain LOV2 from Arabidopsis thaliana, or mutants thereof; Preferably, the mutant is a cycle rearrangement mutant or a mutant with altered response speed; Preferably, the LOV domain is AsLOV2, for example comprising the sequence shown in SEQ ID NO: 1; Preferably, the LOV domain is cpLOV27, for example comprising the sequence shown in SEQ ID NO:

2.

3. The light-controlled repressor protein according to claim 1 or 2, wherein The insertion position is selected from the following amino acid positions of the LacI protein: between positions 335 and 336, between positions 314 and 315, between positions 315 and 316, between positions 316 and 317, between positions 334 and 335, between positions 336 and 337, between positions 337 and 338, between positions 338 and 339, between positions 152 and 153; Preferably, the insertion position is between positions 335 and 336 of the LacI protein.

4. The light-controlled repressor protein according to claim 1 or 2, wherein The insertion position is selected from the following amino acid positions of the LacI protein: between positions 311 and 312, between positions 153 and 154; Preferably, the insertion position is between positions 311 and 312 of the LacI protein.

5. The light-controlled repressor protein according to any one of claims 1 to 4, wherein The LacI protein is wild type; Preferably, the wild-type LacI protein comprises the sequence shown in SEQ ID NO:

26.

6. The light-controlled repressor protein according to any one of claims 1 to 4, wherein The LacI protein is a modified LacI protein, which comprises an amino acid substitution selected from the following compared to the wild-type LacI protein: (i) the amino acid at position 220 is substituted with F, and / or, (ii) the amino acid at position 84 is substituted with E, C, S, T, or I; Preferably, the modified LacI protein comprises the sequence shown in SEQ ID NO: 27 or 28, or comprises a sequence in which the amino acid at position 84 is substituted with C, S, T, or I compared with SEQ ID NO: 27 or 28.

7. The light-controlled repressor protein according to any one of claims 1 to 6, wherein The N-terminus and / or C-terminus of the LOV domain is optionally connected to the LacI protein via a peptide linker.

8. The light-controlled repressor protein according to any one of claims 1 to 7, comprising a sequence as shown in any one of SEQ ID NOs: 11, 29, 6-8, 10, 12-14, 16 or a sequence as shown in SEQ ID NO: 3 or 17; Preferably, the light-controlled repressor protein comprises the sequence shown in SEQ ID NO: 11 or 29; Preferably, the light-controlled repressor protein comprises the sequence shown in SEQ ID NO:

3.

9. A nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein according to any one of claims 1 to 8.

10. A vector comprising the nucleic acid construct according to claim 9.

11. The vector of claim 10, comprising a first nucleic acid construct and a second nucleic acid construct, wherein: The first nucleic acid construct comprises the nucleotide sequence encoding the light-controlled repressor protein, and the second nucleic acid construct comprises a promoter, a LacO operator, and a target gene or a cloning site for integrating a target gene; Preferably, the first nucleic acid construct and the second nucleic acid construct are located in different expression cassettes.

12. The vector according to claim 11, wherein The LacO operator gene contained in the second nucleic acid construct is selected from LacO1, LacOid or a combination thereof.

13. The vector according to claim 11 or 12, wherein The LacO operator gene contained in the second nucleic acid construct comprises at least one copy (e.g., 1 to 8 copies, such as 1, 2, 3, 4, 5, 6, 7, 8, such as 3 to 5 copies) of the LacO1 operator sequence; Preferably, the LacO1 operator sequence comprises the sequence shown in SEQ ID NO:

24.

14. The vector according to claim 13, wherein The LacO operator gene contained in the second nucleic acid construct further comprises LacOid; Preferably, the LacOid is located downstream of LacO1; Preferably, the LacO operator comprises LacO1 and LacOid from 5' to 3' direction.

15. The vector according to any one of claims 11 to 14, wherein The promoter contained in the second nucleic acid construct is selected from: T7 promoter of T7 phage, lac promoter, tac promoter, and lacUV5 promoter.

16. The vector according to any one of claims 11 to 15, wherein The first nucleic acid construct further comprises a promoter operably linked to the nucleotide sequence encoding the light-controlled repressor protein; Preferably, the promoter is selected from the group consisting of wild-type LacI promoter, LacUV5 promoter, tac promoter, and trc promoter.

17. A host cell comprising the nucleic acid construct of claim 9 or the vector of any one of claims 10 to 16; Preferably, the host cell is a prokaryotic cell; Preferably, the host cell is Escherichia coli.

18. The host cell according to claim 17, wherein The host cell is Escherichia coli, and the Escherichia coli has an exogenous nucleotide sequence encoding the light-controlled repressor protein according to any one of claims 1 to 8 integrated into its genome; Preferably, the endogenous LacI gene of the Escherichia coli is disrupted; Preferably, both copies of the endogenous LacI gene of the Escherichia coli are replaced with the exogenous nucleotide sequence; Preferably, one copy of the endogenous LacI gene of the Escherichia coli is replaced by the exogenous nucleotide sequence, and the other copy of the endogenous LacI gene is knocked out.

19. The host cell according to claim 18, wherein The Escherichia coli further comprises the vector according to any one of claims 11-16.

20. A system for regulating the expression of a target gene, comprising: (1) a first nucleic acid construct comprising a nucleotide sequence encoding the light-controlled repressor protein according to any one of claims 1 to 8; (2) A second nucleic acid construct comprising a promoter, a LacO operator, and a second nucleic acid construct of a target gene.

21. The system of claim 20, wherein: The second nucleic acid construct is as defined in any one of claims 11-15.

22. The system of claim 20 or 21, wherein: The second nucleic acid construct comprises a plurality of target genes arranged in tandem; Preferably, additional promoters are optionally inserted between the multiple target genes.

23. The system of any one of claims 20 to 22, wherein: The first nucleic acid construct further comprises a promoter operably linked to the nucleotide sequence encoding the light-controlled repressor protein; Preferably, the promoter is selected from the group consisting of wild-type LacI promoter, LacUV5 promoter, tac promoter, and trc promoter.

24. The system of any one of claims 20 to 23, wherein: (1) The system comprises at least two of the first nucleic acid constructs, one of which is integrated into the genome of the host cell, and the other and the second nucleic acid construct are present on a vector (e.g., an expression vector); wherein the at least two first nucleic acid constructs are identical to or different from each other; preferably, the vector is defined in any one of claims 11 to 16; or, (2) The first nucleic acid construct and the second nucleic acid construct are present on a vector (eg, an expression vector); preferably, the vector is defined in any one of claims 11 to 16; or, (3) the first nucleic acid construct is integrated into the genome of the host cell, and the second nucleic acid construct is present on a vector (e.g., an expression vector); Preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli.

25. A kit comprising a host cell and an expression vector, wherein: (1) The host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein according to any one of claims 1 to 8 integrated into its genome; and the expression vector comprises a first nucleic acid construct and a second nucleic acid construct, wherein the first nucleic acid construct comprises the exogenous nucleotide sequence encoding the light-controlled repressor protein, and the second nucleic acid construct comprises a promoter, a LacO operator gene, and a cloning site for integrating a target gene; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli, such as defined in claim 18; or, (2) The host cell has not integrated the exogenous nucleotide sequence encoding the light-controlled repressor protein into its genome; and the expression vector comprises the first nucleic acid construct and the second nucleic acid construct; preferably, the host cell is a prokaryotic cell, such as Escherichia coli; or, (3) The host cell has an exogenous nucleotide sequence encoding the light-controlled repressor protein according to any one of claims 1 to 8 integrated into its genome; and the expression vector comprises the second nucleic acid construct; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli, such as defined in claim 18; Preferably, the second nucleic acid construct is as defined in any one of claims 11-15.

26. A method for regulating the expression of a target gene, comprising: (1) providing the system according to any one of claims 20 to 24 in a host cell; (2) Cultivating the host cell under conditions that allow expression of the target gene and inducing expression of the target gene.

27. The method of claim 26, wherein: Step (1) comprises: (i) providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises an exogenous nucleotide sequence encoding the light-operated repressor protein according to any one of claims 1 to 8 integrated into its genome; preferably, the expression vector is defined in any one of claims 11 to 16; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli, for example, as defined in claim 18; or, (ii) providing an expression vector comprising the first nucleic acid construct and the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell does not contain the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome; preferably, the expression vector is defined in any one of claims 11 to 16; preferably, the host cell is a prokaryotic cell, such as Escherichia coli; or, (iii) providing an expression vector comprising the second nucleic acid construct in the system; introducing the expression vector into a host cell, wherein the host cell comprises the exogenous nucleotide sequence encoding the light-controlled repressor protein integrated into its genome; preferably, the host cell is a prokaryotic cell; preferably, the host cell is Escherichia coli, such as defined in claim 18.

28. The method of claim 26 or 27, wherein: The light-controlled repressor protein is defined in claim 3, and the induction conditions in step (2) include: culturing the host cell under dark conditions to induce the expression of the target gene; Preferably, the method further comprises culturing the recombinant host cell under blue light conditions to inhibit the expression of the target gene.

29. The method of claim 26 or 27, wherein: The light-controlled repressor protein is defined in claim 4, and the induction conditions in step (2) include: culturing the host cell under blue light conditions to induce the expression of the target gene; Preferably, the method further comprises culturing the host cell under dark conditions to inhibit the expression of the target gene.

30. Use of the light-controlled repressor protein according to any one of claims 1 to 8, the nucleic acid construct according to claim 9, the vector according to any one of claims 10 to 16, the host cell according to any one of claims 17 to 19, the system according to any one of claims 20 to 24, or the kit according to claim 25 for regulating the expression of a target gene; Preferably, the use comprises regulating protein expression; Preferably, the use comprises modulating metabolic pathways and / or biosynthesis.

Citation Information

Cited By

  • Pichia pastoris light-controlled transcription regulation system and use thereof

    WO2025237317A1